Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following Novo Nordisk's announcement on June 23, 2025, to terminate its partnership with Hims & Hers due to these deceptive practices, Hims & Hers' stock price dropped by over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. due to allegations of deceptive promotion and sale of illegitimate versions of Wegovy®, leading to a significant drop in the company's stock price [2][3]. Group 1: Allegations and Impact - Hims & Hers Health, Inc. announced a collaboration with Novo Nordisk on April 29, 2025, to sell Wegovy® on its platform [2]. - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing deceptive practices that jeopardized patient safety, resulting in a 34.6% decline in Hims' share price, closing at $41.98 [2]. - The lawsuit claims that Hims failed to disclose its engagement in selling illegitimate versions of Wegovy® and the risk of partnership termination with Novo Nordisk [3]. Group 2: Legal Proceedings - Shareholders interested in leading the class action must file a motion by August 25, 2025, and can remain absent class members if they choose not to participate [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) is leveraging artificial intelligence (AI) to transform healthcare delivery, aiming for a more personalized, scalable, and accessible approach [1][6] - The company appointed Mo Elshenawy as CTO to lead AI integration, focusing on creating an AI-powered healthcare platform that enhances diagnosis, treatment, and delivery [1][6] - Hims & Hers raised $870 million in convertible notes to fund AI tools and expand personalized treatment options, reflecting its commitment to modernizing healthcare infrastructure [2][6] AI Integration and Innovations - Hims & Hers is developing an AI-driven healthcare platform that includes initiatives like the intelligent MedMatch routing system to improve diagnostic accuracy and patient experience [2] - Teladoc Health, Inc. (TDOC) is also utilizing AI to enhance its virtual care ecosystem, focusing on intelligent triage and predictive analytics to improve patient outcomes [3] - Tempus AI, Inc. (TEM) is embedding AI in precision medicine, particularly in oncology and neurogenomics, to optimize clinical workflows and support real-time clinical decision-making [4] Financial Performance and Estimates - Hims & Hers shares have increased by 95.7% year-to-date, significantly outperforming the industry growth of 19.7% [5] - The Zacks Consensus Estimate predicts a 174.1% improvement in HIMS' earnings per share from 2024 to 2025 [7] - HIMS' forward 12-month price-to-sales ratio is 4.1X, lower than the industry average of 5.8X but higher than its three-year median of 2.3X [9]

Core Viewpoint - Investors with significant losses in Hims & Hers Health, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - The lawsuit alleges that between April 29, 2025, and June 23, 2025, Hims failed to disclose that it was involved in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that there was a substantial risk of termination of Hims' collaboration with Novo Nordisk due to these undisclosed actions [3]. - As a result of the aforementioned issues, the positive statements made by Hims regarding its business operations and prospects were materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in Hims & Hers Health, Inc. are encouraged to contact the Law Offices of Howard G. Smith before August 25, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email or phone to discuss their legal rights and options regarding the class action [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. Legal Allegations - The class action lawsuit alleges that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose risks associated with its collaboration with Novo Nordisk [2]. - Specific allegations include the deceptive promotion and selling of illegitimate versions of Wegovy, which allegedly put patient safety at risk [2][3]. Partnership Termination - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing concerns over deceptive practices [3]. - Following this announcement, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the class period can seek appointment as lead plaintiff in the class action lawsuit [4]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [4]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases [5].

NEW YORK, July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=155244&from=4 CLASS PERIOD: April 29, ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a l ...

Core Viewpoint - Hims & Hers Health has experienced significant volatility, with a recent decline of 16% in stock price, raising concerns among investors despite its strong fundamentals and growth potential [6][12]. Financial Performance - Hims & Hers reported revenue of $586 million for the latest quarter, marking a 111% year-over-year increase [14]. - The company achieved an all-time high of 2.4 million subscribers, reflecting a 38% annualized growth rate [14]. - Free cash flow for the quarter was reported at $50.1 million, nearly five times the $11.9 million from the same quarter the previous year [14]. Market Position and Strategy - Hims & Hers operates a subscription business model, providing stable and predictable cash flows, which is particularly valuable in volatile market conditions [13]. - The stock is currently trading at 66% of its 52-week high, suggesting a potential turnaround opportunity for investors [15]. Recent Developments - The stock initially surged over 100% following a partnership announcement with Novo Nordisk, which was later retracted, leading to the recent stock price decline [7][8]. - Despite the partnership's dissolution, the underlying reasons for the stock's previous rally remain intact, indicating continued growth potential [8][10]. Analyst Ratings and Forecast - The 12-month stock price forecast for Hims & Hers is $39.58, indicating a potential downside of 16.58% from the current price of $47.45 [12]. - Analysts have rated the stock as "Reduce," suggesting caution among investors [17].